Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-150003	Application No. 10/010,283
(Use several sheets if necessary)		Applicant Carl-Axel Bauer et al.	
		Filing Date November 13, 2001	Group Art Unit 1617

	Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner	Desig.		
Initial	ID	Document	
/JK/	A1	Ankerst <i>et al.</i> , "Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma," Pulm Pharmacol Ther., 16:147-51, 2003.	
жоооооо	A2	Arvidsson <i>et al.</i> , "Inhaled formoterol during one year in asthma: a comparison with salbutamol," Eur Respir J, 4:1168-1173, 1991.	
000000000000000000000000000000000000000	A3	Aubier et al., "Salmeterol/Fluticasone propionate (50/500 µg) in combination in a Diskus® inhaler (Seretide®) is effective and safe in the treatment of steroid-dependent asthma," Respir. Med. 93:876-884, 1999.	
000000000000000000000000000000000000000	A4	Bartow <i>et al.</i> , "Formoterol: An Update of its Pharmacological Properties and Therapeutic Efficacy in the Management of Asthma," Drugs, 55(2):303-322, 1998.	
	A5	Bond, "A strategy that works," New Zealand Medical Journal, p. 369, 28 August 1991.	
***************************************	A6	"The British Guidelines on Asthma Management 1995 Review and Position Statement," Thorax, 52(Suppl 1):S1-21, 1997.	
80	A7	Collins et al., "The Use of Corticosteroids in the Treatment of Acute Asthma," Quarterly Journal of Medicine, New Series, XLIV:259-73, 1975.	
000000000000000000000000000000000000000	A8	Corren et al., "Twelve-Week, Randomized, Placebo-Controlled, Multicenter Study of the Efficacy and Tolerability of Budesonide and Formoterol in One Metered-Dose Inhaler Compared with Budesonide Alone and Formoterol Alone in Adolescents and Adults with Asthma," Clinical Therapeutics, 29(5):823-843, 2007.	
	A9	Costain et al., "Guidelines for management of asthma in adults: I—chronic persistent asthma," BMJ, 301:651-653, 1990.	
	A10	Devidayal <i>et al.</i> , "Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma," Acta Paediatr, 88:835-840, 1999.	
000000000000000000000000000000000000000	A11	Ebden <i>et al.</i> , "Comparison of two high dose corticosteroid aerosol treatments, beclomethasone dipropionate (500 μg/day) and budesonide (1600 μg/day), for chronic asthma," Thorax, 41:869-874, 1986.	
000	A12	Ellul-Micallef and Johansson, "Acute Dose-Response Studies in Bronchial Asthma with a New Corticosteroid, Budesonide," Br. J. Clin. Pharmac., 15:419-422, 1983.	
***************************************	A13	01:107-173, 1980.	
***************************************	A14	Engel <i>et al.</i> , "Single-dose inhaled budesonide in subjects with chronic asthma," Allergy, 46:547-553, 1991.	
000	A15	·	
800000000000000000000000000000000000000	A16	1999.	
***************************************	A17	"Foradil: Fast relief that lasts," Ciba-Geigy Limited, Switzerland, Medical and Pharmaceutical Information, 1993	
V	A18	Pneumology, Freiberg, Germany, September 1989.	
/JK/	A19	Hett <i>et al.</i> , "Large-Scale Synthesis of Enantic- and Diasteromerically Pure (R,R)-Formoterol," Org. Process Res. Dev., 2:96-99, 1998.	

Examiner Signature /Jennifer Kim/	Date Considered 03/02/2009
EXAMINER: Initials citation considered. Draw line through citation if n next communication to applicant.	ot in conformance and not considered. Include copy of this form with Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attomey's Docket No. 06275-150003	Application No. 10/010,283
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Carl-Axel Bauer et al.	
		Filing Date November 13, 2001	Group Art Unit 1617

(Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document	
/JK/	A20	Jackson <i>et al.</i> , "Benefit-Risk Assessment of Long-Acting β_2 -Agonists in Asthma," Drug Safety, 27(4):243-270, 2004.	
000000000000000000000000000000000000000	A21	Kesten <i>et al.</i> , "A Three-Month Comparison of Twice Daily Inhaled Formoterol Versus Four Times Daily Inhaled Albuterol in the Management of Stable Asthma," Am Rev Respir Dis, 144:622-625, 1991.	
000	A22	Kumar et al., "Transient Effect of Inhaled Fluticasone on Airway Mucosal Blood Flow in Subjects with and without Asthma," Am J Respir Crit Care Med, 161:918-921, 2000.	
000000000000000000000000000000000000000	A23	Lampa et al., "Antitracheobronchospastic Interaction In Vitro and In Vivo between Salbutamol and Flunisolide," Drugs Exptl. Clin. Res., XI(9):653-658, 1985.	
000000	A24	1997.	
00000000	A25	McDonald <i>et al.</i> , "Evaluation of the combination inhaler of salbutamol and beclomethasone dipropionate in the management of asthma," Curr. Med. Res. Opin., 11(2), 1988.	
00000000000	A26	McFadden, "Inhaled Glucocorticoids and Acute Asthma: Therapeutic Breakthrough or Nonspecific Effect?," Am J Respir Crit Care Med, 157:677-678, 1998.	
0000000	A27	Monthly Index of Medical Specialties (MIMS), Asthma, COPD, September 2007.	
	A28	Monthly Index of Medical Specialties (MIMS), Bronchodilators and anti-inflammatories, December 1991.	
	A29	Monthly Index of Medical Specialties (MIMS), Respiratory System, December, 1991.	
	A30	Moore et al., "Long-acting Inhaled β_2 -Agonists in Asthma Therapy," Chest, 113:1095-1108, 1998.	
	A31	Nana et al., "High-Dose Inhaled Budesonide May Substitute for Oral Therapy After an Acute Asthma Attack," Journal of Asthma, 35:647-655, 1998.	
	A32	National Asthma Education and Prevention Program, "Guidelines for the Diagnosis and Management of Asthma," Expert Panel Report 2 July 1997 No. 97-4051.	
800	A33	Nyholm <i>et al.</i> , "Therapeutic advantages of twice-daily over four-times daily inhalation budesonide in the treatment of chronic asthma," Eur J Respir Dis, 65:339-345, 1984.	
800	A34	The Patents Act 1953 Exhibit "CRWB1." 1998	
0000	A35	The Patents Act 1953 Exhibit "CRWB3." 1998	
0000	A36	The Patents Act 1953 Exhibit "CRWB4." 1998	
	A37	The Patents Act 1953 Exhibit "CRWB5." 1998	
800000	A38	The Patents Act 1953 Exhibit "CRWB6." 1998	
\$0000000000000000000000000000000000000	A39	J., 13:988-992, 1999.	
V	A40	Rabe <i>et al.</i> , "Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomized controlled, double-blind study," Lancet, 368:744-753, 2006.	
/JK/	A41	Rabe et al., "Budesonide/Formoterol in a Single Inhaler for Maintenance and Relief in Mild-to-Moderate Asthma," Chest, 129:246-256, 2006.	

Examiner Signature	Date Considered	
/Jennifer Kim/	03/02/2009	
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-150003	Application No. 10/010,283
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Carl-Axel Bauer et al.	
		Filing Date November 13, 2001	Group Art Unit 1617

	Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Dogument	
/JK/	A42	Document Rees, " β_2 Agonists and asthma," BMJ, 302:1166-1167, 1991.	
/JIN/		Posenhora at al. "Pelative systemic dose potency and tolerability of inhaled formateral and	
300000	A43	salbutamol in healthy subjects and asthmatics," Eur J. Clin Pharmacol., 56:363-370, 2000.	
	A44	Rodrigo et al., "Inhaled Flunisolide for Acute Severe Asthma," Am J Respir Crit Care Med, 157:698-703, 1998.	
	A45	Rodrigo et al., "Acute Asthma in Adults: A Review," Chest, 125:1081-1102, 2004.	
	A46	Ryrfeldt <i>et al.</i> , "Pulmonary disposition of the potent glucocorticoid budesonide evaluated in an isolated perfused rat lung model," Biochem Pharmacol., 38:17-22, 1989.	
000000000000000000000000000000000000000	A47	Schuh et al., "A Comparison of Inhaled Fluticasone and Oral Prednisone For Children with Severe Acute Asthma," New England Journal of Medicine, 343:689-694, 2000.	
0000000000	A48	1990.	
000000000	A49	Dis. Chest, Vol. 75, pages 215-217 (1981).	
000000000000000000000000000000000000000	A50	Dexamethasone in Acute Bronchial Asthma," Annals of Allergy, 56:406-409, 1986.	
000000000000000000000000000000000000000	A51	Sykes <i>et al.</i> , "A study of the duration of the bronchodilator effect of 12 ug and 24 ug of inhaled formoterol and 200 ug inhaled salbutamol in asthma," Respir. Med., 84:135-138, 1990.	
000000000000000000000000000000000000000	A52	Tan et al., "Systemic Corticosteroid Rapidly Reverses Bronchodilator Subsensitivity induced by Formoterol in Asthmatic Patient", Am. J. Respiratory and Critical Care Medicine, 156:28-35, 1997.	
000000000000000000000000000000000000000	A53	Tattersfield <i>et al.</i> on behalf of the Facet International Study Group, "Exacerbations of Asthma," Am J Respir Crit Care Med, 160:594-599, 1999.	
000000000	A54	The Dialog Corporation, "Formoterol launched in Switzerland", Accession No. S002557609000, 10/31/1990.	
0000000	A55	The Merck Manual of Diagnosis and Therapy, 16 th edition, 1992, page 653.	
	A56	Trechsel, "Foradil in medical practice: 7 case studies," Ciba-Geigy Limited, Switzerland (1992).	
	A57	Treschel, AM Conference Report, A new long-acting beta-stimulator 1991	
000000000000000000000000000000000000000	A58	U.S. Department of Health and Human Services, "Practical Guide for the Diagnosis and Management of Asthma," October 1997 NIH Publication No. 97-4053.	
	A59	in ragweed-induced rhinitis," J. Allergy Clin. Immunology, 79:887-892, 1987.	
V	A60	1991.	
/JK/	A61	Wallin et al., "Formoterol, a new long acting beta ₂ agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma," Thorax, 45:259-261, 1990.	

Examiner Signature	Date Considered	
/Jennifer Kim/	03/02/2009	
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		